Product Details
| Product Name:
TRC051384 |
CAS No.:
867164-40-7 |
| Purity:
98.79% |
Supply Ability:
10g |
| Release date:
2025/07/20 |
Product Introduction
Bioactivity
| Name | TRC051384 |
| Description | TRC051384 is a heat shock protein 70 (HSP70) inducer that reduces stroke-associated neuronal damage and increases survival in a rat model of transient ischemic stroke, activates heat shock factor-1 and leads to elevated molecular chaperone and anti-inflammatory activity, and enhances Hsp72 expression in neurons and glial cells. |
| Cell Research | HeLa cell transiently co-transfected with heat shock elements-luciferase reporter and normalization vector, β-galactosidase are treated with vehicle or TRC051384 (12.5 and 25 μM) for 4 hours. Cell lysates are then prepared and analyzed for luciferase and β-galactosidase activity[1]. |
| In vitro | TRC051384 significantly enhances HSP70B mRNA expression hundreds of times in both HeLa cells and rat primary mixed neurons in a dose-dependent fashion. Additionally, it markedly boosts HSF1 transcriptional activity and luciferase recovery upon treatment, following a dose-responsive pattern. Furthermore, TRC051384 demonstrates substantial inhibitory effects on LPS-induced TNF-α expression in the differentiated THP-1 cell line, achieving 60% inhibition at 6.25 μM and 90% inhibition at 12.5 μM [1]. |
| In vivo | Administering TRC051384 significantly diminishes stroke-related neuronal damage and disability in a rat model of transient ischemic stroke, achieving an 87% reduction in the area of the penumbra recruited to infarct and a 25% reduction in brain edema, even when treatment commences 8 hours after ischemia onset. Additionally, initiating TRC051384 treatment 4 hours post-ischemia onset notably enhances survival rates, with a 50% improvement by day 2 and a 67.3% increase by day 7. The mechanism underlying TRC051384's efficacy involves the induction of HSP70 through HSF1 activation, which amplifies chaperone and anti-inflammatory activities[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 16.67 mg/mL (35.8 mM), Sonication is recommended.
|
| Keywords | TRC-051384 | TRC051384 | Inhibitor | inhibit | HSP70 | HSP | Heat shock proteins |
| Inhibitors Related | Ethoxyquin | SNX0723 | Tamoxifen | SNX2112 | Ganetespib | Teprenone | Elesclomol | Rifabutin | Palmitic acid | Paeoniflorin | Tamoxifen Citrate | 17-AEP-GA |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Endoplasmic Reticulum Stress Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Covalent Inhibitor Library | Cytoskeletal Signaling Pathway Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2628506-54-5
$55.00 / 1mg
-
CAS:17618-08-5
$70.00 / 1mg
-
CAS:1333327-56-2
$64.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1.00/1g |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-23 |
United States